|Revision ID||Type||Time Submitted||Versioning Comment|
|14||Therapy||01/27/2017 9:53 PM||Initial version | MET | amplification|
|Variant(s)||MET copy number gain|
|Tumor(s)||Clear Cell Renal Cell Carcinoma|
MET amplification may be associated with sensitivity to MET inhibitors. MET amplification is associated with resistance to EGFR inhibitors in EGFR mutated lung cancer. MET alterations are commonly associated with papillary renal-cell carcinoma and it is very rare in clear cell renal cell carcinoma.
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.